• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Phar­ma is bet­ting big on con­nect­ing po­ten­tial pa­tients to its med­ica­tions. It's just the be­gin­ning

Last year
Pharma
Marketing

Zymeworks re­moves CFO; Gilead ex­tends Nurix deal

Last year
News Briefing

Acor­da files for bank­rupt­cy, agrees to sell MS drug and oth­er as­sets to Merz for $185M

Last year
Deals
Pharma

Ipsen boards ADC train in $900M pact with Sutro

Last year
Deals
Pharma

Grit­stone's Phase 2 can­cer vac­cine tri­al miss­es the mark, stock spi­rals down

Last year
R&D

Lon­za taps Siegfried leader Wolf­gang Wien­and as new CEO

Last year
People
Manufacturing

Three more I-Mab ex­ecs ex­it af­ter US/Chi­na op­er­a­tions split

Last year
People
China

Verve paus­es lead base edit­ing pro­gram af­ter safe­ty event, switch­es fo­cus to fol­low-up can­di­date near clin­ic

Last year
R&D
Cell/Gene Tx

Roivant an­nounces study win in eye dis­ease for Pfiz­er as­set, plans $1.5B share buy­back

Last year
Deals
R&D

Prov­i­dence spin­out Pra­ia Health rais­es $20M

Last year
Startups
Health Tech

Con­gress' Chi­na hawks seek to add biotech sup­pli­ers to Pen­ta­gon warn­ing list

Last year
China
FDA+

CBER's Marks points to stock­piles of H5N1 vac­cine as of­fi­cials mon­i­tor re­port­ed hu­man case

Last year
Pharma
FDA+

EU­'s phar­ma leg­isla­tive re­forms 'will scare in­vest­ment away,' Astel­las ex­ec­u­tive says

Last year
Pharma
Law

Gilead part­ners for ball­room danc­ing work­shop on sex­u­al health and HIV pre­ven­tion

Last year
Pharma
Marketing

Eiger files for bank­rupt­cy and will wind down op­er­a­tions af­ter years of set­backs

Last year
People
Pharma

BM­S' con­fir­ma­to­ry tri­al of Kraza­ti hits pri­ma­ry end­point fol­low­ing 2022 ac­cel­er­at­ed ap­proval

Last year
Pharma
FDA+

Liq­uidia wins against Unit­ed Ther­a­peu­tics in patent bat­tle over PAH drug

Last year
Pharma
Law

Omega cuts 35% of work­force; Rhythm, Cer­voMed, Sur­rozen raise new fund­ing

Last year
News Briefing

Caris­ma to lay off staff, drop clin­i­cal CAR-M pro­gram in fa­vor of sec­ond can­di­date

Last year
People
R&D

Disc Med­i­cine blames 'out­sized' place­bo re­sponse on mixed Phase 2 da­ta in rare blood dis­or­der

Last year
R&D

FDA de­lays de­ci­sion on Ap­plied Ther­a­peu­tics’ rare meta­bol­ic dis­ease drug

Last year
FDA+

FDA asks Bio­gen and Ei­sai to pro­vide more da­ta on sub­cu­ta­neous Leqem­bi

Last year
Pharma
FDA+

Q&A: In­sitro CEO Daphne Koller on ‘po­ten­tial­ly de­struc­tive’ AI hype, Nvidi­a's chips, and biotech's da­ta prob­lem

Last year
People
R&D

Con­tineum says it will seek $136M in IPO to back its mid-stage neu­ro drug

Last year
Financing
Startups
First page Previous page 187188189190191192193 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times